RecruitingNot ApplicableNCT07043686

Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

Effect of Cerebrolysin on Early Rehabilitation After Ischemic Stroke at the Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT), University Medical Centre Ljubljana


Sponsor

University Medical Centre Ljubljana

Enrollment

30 participants

Start Date

Jun 13, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The study evaluates the effect and safety of Cerebrolysin administered during early rehabilitation in patients with moderate neurological impairment after acute ischemic stroke, conducted at the Department of Vascular Neurology and Intensive Neurological Therapy, UMC Ljubljana.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Being able to perform ARAT test Signed informed consent
  • Both sexes, age not specified
  • Acute ischemic stroke confirmed by imaging
  • NIHSS score 6-12
  • No prior stroke or disability (mRS 0 before stroke)
  • \-

Exclusion Criteria3

  • Not being able to perform ARAT test
  • Previous stroke or disability (mRS > 0)
  • The patient unable to understand instructions

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCerebrolysin treatment

The patients will receive Cerebrolysin treatment, 10 days consecutively, 30 ml/day, intravenous infusion diluted up to 100 ml of 0.9% saline in 15 minutes.

OTHERStandard treatment (including neurorehabilitation) of acute ischemic stroke

"Standard treatment" entails acute ischemic stroke reperfusion treatment according to international guidelines and local policies, instituting secondary preventive treatment, a proper management of stroke risk factors and neurorehabilitation according to patient's needs: locomotor physiotherapy, occupation therapy, speech therapy, and neuropsychological assessment.


Locations(1)

UMC Ljubljana - Department of Vascular Neurology and Intensive Neurological Therapy (KOVNINT)

Ljubljana, Slovenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07043686


Related Trials